docetaxel anhydrous has been researched along with Respiratory Tract Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, J; Asaga, T; Fujii, H; Inoue, K; Kimura, M; Kurosumi, M; Sano, M; Sato, N; Tabei, T; Yamamoto, N | 1 |
1 trial(s) available for docetaxel anhydrous and Respiratory Tract Neoplasms
| Article | Year |
|---|---|
Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Respiratory Tract Neoplasms; Risk Assessment; Skin Neoplasms; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2006 |